search
Back to results

Can we Achieve 'High-quality' Weight Loss Through Supplementation and Exercise? The TRIM MUSCLE Study

Primary Purpose

Overweight, Obesity

Status
Recruiting
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Muscle5 and TRIM7
Mixed exercise
Sponsored by
Exerkine Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Overweight focused on measuring Overweight, Obesity, Exercise, Supplementation, Aerobic training, Resistance training, Insulin sensitivity, Sex differences, Inflammation, Oxidative stress, Weight management, Antioxidants, Protein

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • age 18 - 45 years
  • BMI > 25 kg/m2
  • sedentary (less than one exercise session per week)
  • have had two doses of the COVID-19 vaccine

Exclusion Criteria:

  • renal disease (creatinine > 140)
  • liver disease (i.e. diagnosed NAFLD, NASH, cirrhosis, previous liver transplant)
  • GI disorders (i.e. Colitis, Crohns)
  • cardiovascular disease (recent myocardial infarction (< 6 months), hypertension requiring more than 2 medications, congestive heart failure requiring more than one medication for control, unstable arrhythmia, angina previous stroke with residual hemiparesis)
  • severe osteoarthritis
  • significant weight loss in the 3-month period prior to the study (10% of total body weight)
  • muscular dystrophy
  • severe peripheral neuropathy
  • severe osteoporosis
  • uncontrolled hypertension (>140/90 mmHg)
  • orthopedic problems
  • type I or II diabetes
  • respiratory conditions (i.e. chronic pulmonary obstructive disorder), chronic obstructive pulmonary disease (FVC or FEV1 < 70% of age predicted mean value), and asthma requiring more than two medications
  • individuals with prior bariatric surgery
  • women who have ammenorrhea, dysregulated menstrual cycle, are peri-menopausal, menopausal, pregnant, looking to become pregnant, or nursing
  • medications, including anti-inflammatory medications, more than one glucose lowering medication, insulin, platelet inhibitors, anti-coagulant medications, or Simvastatin (zocor), beta-blockers, or weight loss medications (Orlistat, Saxenda Contrave) or any other medications known to affect protein metabolism (i.e.corticosteroids).
  • inability to take part in the exercise program
  • vegan
  • smoking
  • history of glaucoma or
  • overactive bladder syndrome
  • consumption of more than 10 drinks/week or 2 drinks/d for women and 15 drinks/week or 3 drinks/d for men.
  • history of allergy, sensitivity or strong dislike towards any component of the study products (supplements)
  • have undergone a barium swallow or an infusion of a contrast agent in the past 3 weeks
  • have an implantable electronic device
  • inability to perform exercise as determined by the Get Active Questionnaire (GAQ)
  • inability to consent
  • participants on volitional dietary supplements will be considered on a case-by-case basis, but they will be asked to refrain from intake for at least 2 weeks prior to partaking in this study.

Sites / Locations

  • Michaela Devries-AboudRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Muscle5 and TRIM7

Placebo

Arm Description

MUSCLE5 and TRIM7 natural health product supplementation Name of natural health product (brand name, generic) - MUSCLE 5, chocolate Is this a market-approved natural health product (per Health Canada)? - Yes Dose - 1 scoop Ingredients (per dose) - Whey protein isolate (24g), milk protein isolate (16g), Creatine (3g), Calcium (450mg), Vitamin D (1000 IU) Frequency of administration - Once/day Duration (e.g., six weeks) - 12 weeks Route of administration - Oral Name of natural health product (brand name, generic) - TRIM7 Is this a market-approved natural health product (as per Health Canada)? Yes Dose - 3 capsules Ingredients (per dose) - Alpha lipoic acid (200mg), CoEnzyme Q10 (100mg), beet root extract (250mg), green coffee bean extract (250mg), green tea extract (250mg), forskolin (25mg), Vitamin E (22 mg AT) Frequency of administration - Twice/day Duration (e.g., six weeks) - 12 weeks Route of administration - Oral

Placebo collagen and microcrystalline cellulose intake Placebo Control 1 (Counter to MUSCLE5) Dose - 1 scoop Ingredients (per dose) - Collagen (40g) Frequency of administration - once/day Duration - 12 weeks Route of administration - Oral Placebo Control 2 (Counter to TRIM7) Dose - 3 capsules Ingredients (per dose) - Microcrystalline cellulose (400 mg) Frequency of administration - twice/day Duration - 12 weeks Route of administration - Oral

Outcomes

Primary Outcome Measures

Bodyweight change
scale
BMI change
Body mass index (weight/height squared)
Fat mass change
body composition by DEXA
Lean mass change
body composition by DEXA
Lean mass/fat mass (body composition index) change
body composition by DEXA
Percent body fat change
body composition by DEXA
Waist-to-hip ratio change
measure tape

Secondary Outcome Measures

VO2max change
Maximal aerobic capacity test (gas exchange and indirect calorimetry measured using a metabolic cart and incremental cycle ergometry)
Lower body strength change
1-repetition and 5-repetition maximal strength
Upper body strength change
1-repitition maximal strength and 5-repeitition maximal strength
Appendicular lean mass change
body composition by DEXA
Insulin sensitivity change
Oral glucose tolerance test (OGTT)
Blood lipids change
cholesterol (LDL, HDL, and total cholesterol) and triglycerides
Inflammation CRP change
pro-inflammatory circulatory factor (ng/mL) by Luminex Performance Assay
Inflammation TNF-alpha change
pro inflammatory circulatory factor (pg/ml) by Luminex Performance Assay
Inflammation IL-1 change
pro inflammatory circulatory factor (pg/ml) by Luminex Performance Assay
Inflammation IL-10 change
anti-inflammatory circulatory factors (pg/mL) by Luminex Performance Assay
Inflammation IL-6 change
pro-inflammatory circulatory factor (pg/mL) by Luminex Performance Assay
Antioxidant capacity change
TEAC (trolox equivalent antioxidant assay)

Full Information

First Posted
May 10, 2022
Last Updated
July 7, 2023
Sponsor
Exerkine Corporation
Collaborators
University of Waterloo
search

1. Study Identification

Unique Protocol Identification Number
NCT05384431
Brief Title
Can we Achieve 'High-quality' Weight Loss Through Supplementation and Exercise? The TRIM MUSCLE Study
Official Title
Can we Achieve 'High-quality' Weight Loss Through Supplementation and Exercise? The TRIM MUSCLE Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 15, 2022 (Actual)
Primary Completion Date
March 15, 2024 (Anticipated)
Study Completion Date
March 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Exerkine Corporation
Collaborators
University of Waterloo

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether the combination of two dietary supplements: MUSCLE 5, which contains protein, creatine and vitamin D and TRIM 7, which contains beet extract, caffeine, coenzyme Q10, alpha lipoic acid, forskolin extract, green coffee bean extract, green tea and vitamin E, plus exercise can induce greater 'high-quality' weight loss than exercise alone in overweight and obese men and women. First, the investigators will examine whether the addition of these two supplements to a mixed exercise regime (e.g., aerobic and resistance training) induces greater improvements in typical training adaptations (aerobic capacity, upper & lower body muscle strength, lean mass, ASM, fat mass, % body fat, and lean mass/fat mass). Secondly, the investigators will assess improvements in pro- and anti-inflammatory factors, insulin sensitivity, and blood lipids. Third, the investigators will determine effects on perceived stress, sleep quality, hair & nail growth, and health-related quality of life. Overweight men and women will be randomized to either exercise alone or exercise plus supplement for 12 weeks. Training will include mixed exercise (aerobic and resistance) three days per week and supplements will be taken on a daily basis. Before and after the 12-week training period the investigators will assess A) Body weight, BMI, DXA outcomes (total lean mass, total body fat, % body fat, ASM, and lean mass/fat mass), waist circumference, VO2max, and upper/lower body maximal strength, B) Circulatory inflammatory factors, antioxidants, blood lipids, and oral glucose tolerance/insulin sensitivity (OGTT), C) Perceived stress, sleep quality, hair & nail growth, and health-related quality of life and D) Overall Health Index. Benefits of the study to participants may include weight loss and improved health (irrespective of weight loss). Benefits of the study to the scientific community include improved understanding of how high-quality protein- and antioxidant-containing supplements, combined with mixed exercise, affect weight loss and overall health in men and women. Thus, the investigators will be comparing men and women to determine if the response to supplementation and exercise is similar or different between the sexes.
Detailed Description
The purpose of the proposed study is to determine if the addition of two supplements (TRIM 7 and MUSCLE 5) to an exercise regime can induce more favorable effects on body weight, BMI, body composition (lean mass, fat mass, % body fat, ASM, and lean mass/fat mass), upper & lower body strength, aerobic fitness (VO2max), insulin sensitivity (OGTT), blood lipids (cholesterol and triglycerides), antioxidant capacity (total reducing capacity of plasma), inflammation (TNFα, IL6, CRP, IL- 10) and overall health in overweight men and women. Primary objective/research question*: -Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater 'high-quality' weight loss? Co-primary objectives/research questions*: Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater loss of bodyweight? Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater improvement in body mass index (BMI)? Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater improvement in waist-to-hip ratio? Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater loss of fat mass? Can the addition of TRIM 7 and MUSCLE 5 to an exercise program maintain or improve lean mass? Can the addition of TRIM 7 and MUSCLE 5 to an exercise program maintain or improve lean mass/fat mass ratio (e.g., body composition index)? Secondary objectives/research questions: Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater improvements in muscle strength and aerobic capacity? Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater improvements in insulin sensitivity? Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater reductions in inflammation and greater increases in antioxidant status? Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater improvements in sleep quality, perceived stress, health-related quality of life and the overall health index? Can the addition of TRIM 7 and MUSCLE 5 to an exercise program induce greater improvements in hair & nail growth? Hypotheses: The addition of TRIM 7 and MUSCLE 5 will induce greater 'high-quality' weight loss than exercise alone as evidenced by A) greater loss of fat mass, B) greater gain (or maintenance) of lean mass, C) greater improvement in lean mass/fat mass ratio (e.g., body composition index) D) greater loss of bodyweight E) greater reduction in waist-to-hip ratio and/or F) greater improvement in BMI. The addition of TRIM 7 and MUSCLE 5 will induce greater improvements in muscle strength and aerobic fitness than exercise alone as evidenced by a greater improvement in 1RM and VO2peak than exercise alone. The addition of TRIM 7 and MUSCLE 5 will induce greater improvements in insulin sensitivity (HOMA-IR, glycemic control during an OGTT, Matsuda Index) than exercise alone. The addition of TRIM 7 and MUSCLE 5 will induce a greater reduction in inflammation (TNFα, IL6, CRP, IL- 10) and induce a greater improvement in antioxidant status (GSH:GSSG, CuZn SOD, MnSOD, catalase, total reducing capacity of plasma) than exercise alone. The addition of TRIM 7 and MUSCLE 5 will induce greater improvements in sleep quality, perceived stress, health-related quality of life, and an overall health index than exercise alone. The addition of TRIM 7 and MUSCLE 5 will induce greater improvements in hair & nail growth than exercise alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight, Obesity
Keywords
Overweight, Obesity, Exercise, Supplementation, Aerobic training, Resistance training, Insulin sensitivity, Sex differences, Inflammation, Oxidative stress, Weight management, Antioxidants, Protein

7. Study Design

Primary Purpose
Other
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Randomized, placebo controlled, parallel group design.
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
All Exerkine and University of Waterloo research staff will be blinded to the study.
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Muscle5 and TRIM7
Arm Type
Active Comparator
Arm Description
MUSCLE5 and TRIM7 natural health product supplementation Name of natural health product (brand name, generic) - MUSCLE 5, chocolate Is this a market-approved natural health product (per Health Canada)? - Yes Dose - 1 scoop Ingredients (per dose) - Whey protein isolate (24g), milk protein isolate (16g), Creatine (3g), Calcium (450mg), Vitamin D (1000 IU) Frequency of administration - Once/day Duration (e.g., six weeks) - 12 weeks Route of administration - Oral Name of natural health product (brand name, generic) - TRIM7 Is this a market-approved natural health product (as per Health Canada)? Yes Dose - 3 capsules Ingredients (per dose) - Alpha lipoic acid (200mg), CoEnzyme Q10 (100mg), beet root extract (250mg), green coffee bean extract (250mg), green tea extract (250mg), forskolin (25mg), Vitamin E (22 mg AT) Frequency of administration - Twice/day Duration (e.g., six weeks) - 12 weeks Route of administration - Oral
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo collagen and microcrystalline cellulose intake Placebo Control 1 (Counter to MUSCLE5) Dose - 1 scoop Ingredients (per dose) - Collagen (40g) Frequency of administration - once/day Duration - 12 weeks Route of administration - Oral Placebo Control 2 (Counter to TRIM7) Dose - 3 capsules Ingredients (per dose) - Microcrystalline cellulose (400 mg) Frequency of administration - twice/day Duration - 12 weeks Route of administration - Oral
Intervention Type
Dietary Supplement
Intervention Name(s)
Muscle5 and TRIM7
Intervention Description
Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks
Intervention Type
Other
Intervention Name(s)
Mixed exercise
Intervention Description
Mixed exercise (aerobic and resistance) three days per week for 12 weeks
Primary Outcome Measure Information:
Title
Bodyweight change
Description
scale
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
BMI change
Description
Body mass index (weight/height squared)
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Fat mass change
Description
body composition by DEXA
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Lean mass change
Description
body composition by DEXA
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Lean mass/fat mass (body composition index) change
Description
body composition by DEXA
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Percent body fat change
Description
body composition by DEXA
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Waist-to-hip ratio change
Description
measure tape
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Secondary Outcome Measure Information:
Title
VO2max change
Description
Maximal aerobic capacity test (gas exchange and indirect calorimetry measured using a metabolic cart and incremental cycle ergometry)
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Lower body strength change
Description
1-repetition and 5-repetition maximal strength
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Upper body strength change
Description
1-repitition maximal strength and 5-repeitition maximal strength
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Appendicular lean mass change
Description
body composition by DEXA
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Insulin sensitivity change
Description
Oral glucose tolerance test (OGTT)
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Blood lipids change
Description
cholesterol (LDL, HDL, and total cholesterol) and triglycerides
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Inflammation CRP change
Description
pro-inflammatory circulatory factor (ng/mL) by Luminex Performance Assay
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Inflammation TNF-alpha change
Description
pro inflammatory circulatory factor (pg/ml) by Luminex Performance Assay
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Inflammation IL-1 change
Description
pro inflammatory circulatory factor (pg/ml) by Luminex Performance Assay
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Inflammation IL-10 change
Description
anti-inflammatory circulatory factors (pg/mL) by Luminex Performance Assay
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Inflammation IL-6 change
Description
pro-inflammatory circulatory factor (pg/mL) by Luminex Performance Assay
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Antioxidant capacity change
Description
TEAC (trolox equivalent antioxidant assay)
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Other Pre-specified Outcome Measures:
Title
Perceived stress change (Perceived Stress Scale)
Description
Perceived Stress Scale (PSS-10; 0 = lowest stress, 40 = highest stress)
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Sleep quality change (Bergen Insomnia Scale)
Description
Bergen Insomnia Scale (0 = lowest insomnia, 42 = highest insomnia)
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Health-related quality of life (SF 36)
Description
36 Item Short Form Survey (SF 36; 0 = maximal disability, 100 = no disability)
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Male hair growth & quality (Merk & Co, 1996)
Description
5 item survey (Merk & Co; 38 = maximal score (highest quality), 5 = lowest score (lowest quality))
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Female hair growth & quality (WHGQ)
Description
4 item survey (WHGQ; 28 = maximal score (highest quality), 4 = lowest score (lowest quality))
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Nail health
Description
5 item survey (25 = maximal score, 5 = lowest score)
Time Frame
baseline 0 weeks ("pre study") to 12 weeks ("post study")
Title
Nail growth change
Description
Ten-day nail growth will be measured by a digital caliper (Mitotoyu 500) three times during the course of the study (baseline, midway, and post).
Time Frame
baseline 0 weeks ("pre study"), 6 weeks ("midway"), and 12 weeks ("post study")

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: age 18 - 45 years BMI > 25 kg/m2 low physical activity level < 150 min/week (< ACSM and CSEP recommendations) have had two doses of the COVID-19 vaccine Exclusion Criteria: renal disease (creatinine > 140) liver disease (i.e. diagnosed NAFLD, NASH, cirrhosis, previous liver transplant) GI disorders (i.e. Colitis, Crohns) cardiovascular disease (recent myocardial infarction (< 6 months), hypertension requiring more than 2 medications, congestive heart failure requiring more than one medication for control, unstable arrhythmia, angina previous stroke with residual hemiparesis) severe osteoarthritis significant weight loss in the 3-month period prior to the study (10% of total body weight) muscular dystrophy severe peripheral neuropathy severe osteoporosis uncontrolled hypertension (>140/90 mmHg) orthopedic problems type I or II diabetes respiratory conditions (i.e. chronic pulmonary obstructive disorder), chronic obstructive pulmonary disease (FVC or FEV1 < 70% of age predicted mean value), and asthma requiring more than two medications individuals with prior bariatric surgery women who have ammenorrhea, dysregulated menstrual cycle, are peri-menopausal, menopausal, pregnant, looking to become pregnant, or nursing medications, including anti-inflammatory medications, more than one glucose lowering medication, insulin, platelet inhibitors, anti-coagulant medications, or Simvastatin (zocor), beta-blockers, or weight loss medications (Orlistat, Saxenda Contrave) or any other medications known to affect protein metabolism (i.e.corticosteroids). inability to take part in the exercise program vegan smoking history of glaucoma or overactive bladder syndrome consumption of more than 10 drinks/week or 2 drinks/d for women and 15 drinks/week or 3 drinks/d for men. history of allergy, sensitivity or strong dislike towards any component of the study products (supplements) have undergone a barium swallow or an infusion of a contrast agent in the past 3 weeks have an implantable electronic device inability to perform exercise as determined by the Get Active Questionnaire (GAQ) inability to consent participants on volitional dietary supplements will be considered on a case-by-case basis, but they will be asked to refrain from intake for at least 2 weeks prior to partaking in this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michaela Devries-Aboud, PhD
Phone
9054147897
Email
m4devrie@uwaterloo.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer Wilkinson
Phone
9054147897
Email
j7wilkin@uwaterloo.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michaela Devries-Aboud, PhD
Organizational Affiliation
Kinesiology and Health Sciences, University of Waterloo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Michaela Devries-Aboud
City
Waterloo
State/Province
Ontario
ZIP/Postal Code
N2L3G1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michaela Devries-Aboud
Phone
9054147897
Email
m4devrie@uwaterloo.ca

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There are no plans of making the clinical trial data at the individual level available to researchers who were not part of the original study team

Learn more about this trial

Can we Achieve 'High-quality' Weight Loss Through Supplementation and Exercise? The TRIM MUSCLE Study

We'll reach out to this number within 24 hrs